Prix Simcere Pharmaceutical Group Limited (2096.HK)

Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 6,815 full-time employees. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces various drugs, including Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions. The firm mainly conducts its businesses in the domestic market and overseas markets.